目的 探討小金片聯(lián)合亮丙瑞林治療子宮內(nèi)膜異位癥的臨床效果。方法 選取2016年1月-2018年6月北京懷柔醫(yī)院收治的子宮內(nèi)膜異位癥患者90例，隨機(jī)分成對照組（45例）和治療組（45例）。對照組皮下注射注射用醋酸亮丙瑞林微球，3.75 mg/次，1次/4周，共治療3次，初次給藥從月經(jīng)周期的第3天開始。治療組在對照組基礎(chǔ)上口服小金片，2片/次，2次/d。兩組患者連續(xù)治療3個月。觀察兩組患者臨床療效，同時比較治療前后兩組患者主要癥狀體征改善情況，及促卵泡刺激素（FSH）、促黃體生成素（LH）、雌二醇（E2）、全血低切黏度（LBV）、紅細(xì)胞聚集指數(shù)（EAI）、紅細(xì)胞比容（HCT）、腫瘤壞死因子-α（TNF-α）、單核細(xì)胞趨化蛋白-1（MCP-1）和糖蛋白抗原125（CA125）水平。結(jié)果 治療后，對照組和治療組臨床有效率分別為82.2%和95.6%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者痛經(jīng)、盆腔痛、性交痛等VAS評分均顯著降低（P<0.05），盆腔包塊直徑、子宮體積則均顯著縮?。?i>P<0.05），且治療組以上主要癥狀體征的改善效果均顯著優(yōu)于對照組（P<0.05）。治療后，兩組血清FSH、LH、E2水平均顯著降低（P<0.05），且治療組比對照組下降更顯著（P<0.05）。治療后，治療組LBV、EAI、HCT值均顯著低于對照組（P<0.05）。治療后，兩組患者血清TNF-α、MCP-1及CA125濃度均顯著下降（P<0.05）；且治療組較同期對照組下降更明顯（P<0.05）。結(jié)論 小金片聯(lián)合亮丙瑞林治療子宮內(nèi)膜異位癥有助于促進(jìn)患者相關(guān)癥狀體征的緩解，調(diào)節(jié)生殖內(nèi)分泌功能，改善機(jī)體淤血及炎癥狀態(tài)，整體療效顯著，安全可靠。

Objective To investigate the clinical effect of Xiaojin Tablets combined with leuprorelin in treatment of endometriosis. Methods Patients (90 cases) with endometriosis in Beijing Huairou Hospital from January 2016 to June 2018 were randomly divided into control (45 cases) and treatment (45 cases) groups. Patients in the control group were subcutaneous injection administered with Leuprorelin Acetate Microspheres for injection for three times, 3.75 mg/time, once every 4 weeks, the initial administration started from the 3 d of the menstrual cycle. Patients in the treatment group were po administered with Xiaojin Tablets on the basis of the control group, 2 tablets/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the improvement of main symptoms and signs, and the level of FSH, LH, E2, LBV, EAI, HCT, TNF-α, MCP-1 and CA125 in two groups before and after treatment was compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 82.2% and 95.6% respectively, and there were differences between two groups (P<0.05). After treatment, the VAS scores of dysmenorrhea, pelvic pain, coital pain in two groups were significantly decreased (P<0.05), the pelvic mass diameter and uterine volume were significantly reduced (P<0.05), and the improvement effect of the main symptoms and signs in the treatment group was significantly better than those in the control group (P<0.05). After treatment, the level of FSH, LH and E2 in two groups was significantly decreased (P<0.05), and which in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, the level of LBV, EAI and HCT in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, the serum level of TNF-α, MCP-1 and CA125 in two groups was significantly decreased (P<0.05), and which in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Xiaojin Tablets combined with leuprorelin in treatment of endometriosis can relieve the related symptoms and signs, regulate reproductive endocrine function, improve the body's congestion and inflammation, has remarkable overall effect with good safety and reliability.

R984